Speaker: Dr Natalie Prow, QIMR and UniSA
Title: A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses
Speaker Biography: Dr Natalie Prow has nineteen years of experience in molecular virology and infectious diseases with a particular focus on the development and use of animal models for infectious diseases including the mosquito-borne flaviviruses, Zika, West Nile, Japanese encephalitis viruses and Alphaviruses, Chikungunya, Ross River and Sindbis viruses. My research has involved the use of molecular biology, immunology and virology to evaluate vaccine candidates, potential virulence determinants and therapeutics. Dr Prow has a current research interest on industry-focused translational outcomes and partners with biotech companies and end users to fast-track vaccine candidates through to clinical trials. Dr Prow holds an Advanced Queensland Research Fellowship, partnered with Sementis Ltd to fast track a Zika/chikungunya vaccine candidate through to clinical trials. She also holds an Adjunct appointment at UniSA Cancer Research Institute, School of Pharmacy and Medical Sciences.